BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ascletis Pharma readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Ascletis Pharma's drugs run\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05024214-994@assetmemo.bio
DTSTAMP:20261121T005446Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Envafolimab: Phase 1/2 readout est. (NCT05024214)
DESCRIPTION:Envafolimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: P
 hase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tu
 mors\nEstimated primary completion: December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/envafolimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05024214
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05112991-994@assetmemo.bio
DTSTAMP:20261121T005446Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Envafolimab: Phase 2 readout est. (NCT05112991)
DESCRIPTION:Envafolimab\, phase 2\, Endometrial Cancer.\nStudy: Study of En
 vafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial C
 ancer\nEstimated primary completion: December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/envafolimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05112991
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07863193-6740@assetmemo.bio
DTSTAMP:20261121T005446Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Denifanstat: Phase 3 readout est. (NCT07863193)
DESCRIPTION:Denifanstat\, phase 3.\nStudy: Phase 3 Study of Denifanstat in 
 Participants With Moderate to Severe Acne (AURORA)\nEstimated primary comp
 letion: August 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 denifanstat#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07863193
URL:https://assetmemo.bio/drug/denifanstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04891198-994@assetmemo.bio
DTSTAMP:20261121T005446Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Envafolimab: Phase 2 readout est. (NCT04891198)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: ENVAFOLIMAB Single-agent Treatme
 nt in Patients With Advanced Solid Tumors\nEstimated primary completion: 3
 0 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/envafo
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04891198
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06123754-994@assetmemo.bio
DTSTAMP:20261121T005446Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Envafolimab: Phase 3 readout est. (NCT06123754)
DESCRIPTION:Envafolimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Pha
 se III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable
  Stage III NSCLC\nEstimated primary completion: 30 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/envafolimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06123754
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743450-211@assetmemo.bio
DTSTAMP:20261121T005446Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:ASC30: Phase 3 readout est. (NCT07743450)
DESCRIPTION:ASC30\, phase 3\, Obesity.\nStudy: A Study of Once-daily Oral A
 SC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesit
 y or Overweight With Type 2 Diabetes\nEstimated primary completion: July 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/asc30#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07743450
URL:https://assetmemo.bio/drug/asc30#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743463-211@assetmemo.bio
DTSTAMP:20261121T005446Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:ASC30: Phase 3 readout est. (NCT07743463)
DESCRIPTION:ASC30\, phase 3\, Obesity.\nStudy: A Study of Once-daily Oral A
 SC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesit
 y or Overweight With Weight-Related Comorbidities\nEstimated primary compl
 etion: July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/asc
 30#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7743463
URL:https://assetmemo.bio/drug/asc30#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04910386-994@assetmemo.bio
DTSTAMP:20261121T005446Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Envafolimab: Phase 2 readout est. (NCT04910386)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: Multicenter Phase 2 Study of Env
 afolimab in Biliary Tract Cancers\nEstimated primary completion: June 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/envafolimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04910386
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
